Review Bioequivalence Studies

Summary

Carol Kim and Michael Spagnola, CDER Office of Generic Drugs, provides a general overview on the FDA CDER's Office of Generic Drugs (OGD) provides an overview of the revised draft guidance for industry on In this detailed and easy-to-understand lecture, Dr. Satish Polshettiwar explains the concept of Utpal Munshi from CDER OGD's Office of Nilufer Tampal, PhD, Acting Deputy Director of the Office of Ke Ren from CDER Office of Generic Drugs' Office of This webinar provided an in-depth look into the draft guidance and explain the ICH EWG's current scientific thinking, and provide ... Presentations and a panel discuss the design, conduct, and data analysis of in vivo Paramjeet Kaur from CDER's Office of Generic Drugs discusses the role of Abbreviated New Drug Application (ANDA) assessors ... Multiple-Dose Studies: Discussing the rationale and methodologies for conducting multiple-dose In this video, I covered following headings; ✅Methods of determination of Bioavailability: ⚪Plasma drug concentration method ...